RL
Richard Law Goldman Sachs Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Viridian Therapeutics
VRDN
$1.52B
| $18.64 | $30 |
61%
upside
| Buy | 28 days ago |
|
2
MoonLake Immunotherapeutics
MLTX
$3.79B
| $59.72 | $82 |
37%
upside
| Buy | 29 days ago |
|
3
Arcutis Biotherapeutics
ARQT
$1.94B
| $16.21 | $18 |
11%
upside
| Neutral | 1 month ago |
|
4
Olema Pharmaceuticals
OLMA
$436M
| $6.35 | $18 |
183%
upside
| Buy | 3 months ago |
|
5
Rocket Pharmaceuticals
RCKT
$349M
| $3.23 | $13 |
302%
upside
| Neutral | 3 months ago |
|
6
Celldex Therapeutics
CLDX
$1.51B
| $22.78 | $31 |
36%
upside
| Neutral | 3 months ago |
|
7
Viking Therapeutics
VKTX
$2.98B
| $26.53 | $30 |
13%
upside
| Neutral | 4 months ago |
|
8
Mineralys Therapeutics
MLYS
$2.2B
| $33.12 | $24 |
28%
downside
| Buy | 6 months ago |
|
9
Merus
MRUS
$5.01B
| $66.23 | $73 |
10%
upside
| Buy | 9 months ago |
|
10
Monte Rosa Therapeutics
GLUE
$303M
| $4.91 | $11 |
124%
upside
| Neutral | 2 years ago |
|
|
11
Olema Pharmaceuticals
OLMA
$436M
| $6.35 | $18 |
183%
upside
| Outperform | 2 years ago |
|
12
Beam Therapeutics
BEAM
$1.88B
| $18.54 | $47 |
154%
upside
| Neutral | 2 years ago |
|
|
13
Mineralys Therapeutics
MLYS
$2.2B
| $33.12 | $37 |
12%
upside
| Outperform | 2 years ago |
|
14
CRISPR Therapeutics
CRSP
$4.8B
| $52.74 | $63 |
19%
upside
| Neutral | 2 years ago |
|
15
Kymera Therapeutics
KYMR
$3.02B
| $42.20 | $37 |
12%
downside
| Neutral | 2 years ago |
|
16
Intellia Therapeutics
NTLA
$1.25B
| $11.62 | $76 |
554%
upside
| Outperform | 2 years ago |
|
17
Arvinas
ARVN
$559M
| $7.61 | $61 |
702%
upside
| Outperform | 2 years ago |
|